Long‐Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease
Canadian Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1155/2024/2364031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, 2024. Verfasst von Ayaz Sapuk und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Transplantational Medicine University Hospital Essen, and Faculty of Medicine University of Duisburg-E…. Hauptthemen laut MEDLINE: Hepatitis D, Chronic, Antiviral Agents, Hepatitis Delta Virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bulevirtide (BLV) is approved for the treatment of chronic hepatitis D (CHD). Because only limited long‐term experience has been reported, we aimed to evaluate the efficacy and safety of BLV treatment in patients with advanced chronic liver disease (ACLD). We performed a retrospective analysis of patients with CHD who received BLV 2 mg/day for >12 months at a tertiary center. Virological response (VR) was defined as a reduction in hepatitis delta virus‐ribonucleic acid (HDV‐RNA) ≥2 log 10 from baseline or HDV‐RNA negativity and biochemical response (BR) as gender‐specific normalization of transaminases. We identified 14 patients (9 men, 5 women; median age of 48 years; interquartile range (IQR) of 37–55), of whom 12 (86%) had suggested or assumed ACLD according to Baveno VI criteria. The median duration of BLV treatment was 26 months (IQR 17–27). During treatment, the mean HDV‐RNA level decreased from log 10 5.58 IU/ml to levels between log 10 2.19 IU/ml and log 10 3.19 IU/ml. HDV‐RNA negativity was achieved in up to 63% after 24 months. VR and BR were 86% and 43% after 12 months, 90% and 60% after 18 months, 75% and 75% after 24 months, and 100% and 50% after 30 months, respectively. Two nonpersisting viral breakthroughs were observed after 24 months of treatment. The Child Pugh score and model of end‐stage liver disease (MELD) scores remained stable or improved in 12 patients (86%). Only one patient developed hepatic decompensation after 24 months of treatment with ascites requiring large‐volume paracentesis which was not associated with viral breakthrough, portal vein thrombosis, or hepatocellular carcinoma. Treatment with BLV beyond one year is effective and safe for patients with CHD and ACLD. Liver function remained stable or improved during treatment in the vast majority of patients, and only one case of hepatic decompensation occurred during a median follow‐up of 26 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology and Transplantational Medicine University Hospital Essen, and Faculty of Medicine University of Duisburg-Essen, Essen, Germany.
- Institute for Virology University Hospital Essen, and Faculty of Medicine University of Duisburg-Essen, Essen, Germany.
ORCID-Profile: Christoph Schramm
Zitieren
APA
Sapuk, A., Steinhoff, L., Huenninghaus, K., Willuweit, K., Rashidi Alavijeh, J., Hild, B., Asar, L., Schmidt, H. H., & Schramm, C. (2024). Long‐Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease. Canadian Journal of Gastroenterology and Hepatology. https://doi.org/10.1155/2024/2364031
Vancouver
Sapuk A, Steinhoff L, Huenninghaus K, Willuweit K, Rashidi Alavijeh J, Hild B, et al. Long‐Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease. Canadian Journal of Gastroenterology and Hepatology. 2024. doi:10.1155/2024/2364031
BibTeX
@article{Sapuk2024,
author = {Sapuk, Ayaz and Steinhoff, Leonie and Huenninghaus, Kristin and Willuweit, Katharina and Rashidi Alavijeh, Jassin and Hild, Benedikt and Asar, Lucia and Schmidt, Hartmut H and Schramm, Christoph},
title = {Long‐Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1155/2024/2364031}
}
EUVIMED